Replies to post #367084 on Amarin Corp Plc (AMRN)

[specopsman]

Nothing so far. Gilead is being tight lipped regarding both the NASH study
(a lot of sites including overseas) and GS 5245
The latter is referenced in their press release but not listed on their website. Not to spread rumors but my take is something may be brewing between Matinas and Gilead. Might not be a buyout but perhaps partnership or sponsorship. Hope this helps.

[Number sleven]

Money,
https://clinicaltrials.gov/ct2/show/results/NCT02781584?term=Vascepa&draw=4&rank=24
I don't know if this is new, but it lists results submitted.
Sleven,

[CaptBeer]

Over the years many trials have undertaken the task of finding a single drug or drug combination to treat or prevent NASH. None, have been successful resulting in an FDA approval. In the trial you reference:

NCT02781584, A study of the Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH). There were 13 Cohorts (Arms) in this trial consisting of various combinations of drugs. VASCEPA was in Cohort #12:

Experimental: Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)
Pre-treatment with Vascepa® (2 x 1 g tablet twice daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + Vascepa® (2 x 1 g tablet twice daily) for 6 weeks

The results were submitted to ClinicalTrials.gov on January 4th but have not been published. I heard a rumor that all cohorts failed to meet endpoints. We will see.